Compare Ambarella Inc (AMBA) vs Tempus AI (TEM) Price & Performance

Ambarella (AMBA) trades at $77.30, down 1.38% on the day, with a bullish technical setup supported by moving averages and key resistance at $81. The company reported three consecutive quarterly EPS beats, with Q1 2027 earnings of $0.11 meeting estimates, while revenue grew 16.9% year-over-year to $100.4 million. A major catalyst is the $800+ million long-term edge AI agreement with Hanwha, signaling strong demand in physical AI markets. However, net income remains negative at -$117.13 million for 2025, though margins are improving.

Outlook: Wall Street is bullish with a $108.67 consensus price target (40% upside), driven by edge AI adoption and auto sector growth. Risks include persistent losses, competitive pressure from larger chipmakers, and execution challenges in scaling new AI contracts. The stock's valuation at 8.21x sales appears reasonable if revenue acceleration continues, but profitability remains key for sustained gains.

Tempus AI (TEM) trades at $58.23, down 5.26% for the day, as the precision medicine technology company continues to show strong revenue growth but significant losses. The stock maintains a bullish technical signal with support at $58 and resistance at $64, while analysts remain optimistic with 61.5% buy ratings and a $63.50 consensus target. Recent FDA approvals for diagnostic tests and expanding AI platform capabilities provide growth catalysts despite ongoing operational losses.

The investment case hinges on Tempus's unique healthcare data platform and AI capabilities driving long-term growth, though substantial GAAP losses and negative cash flow from operations present near-term execution risks. With revenue projected to reach $1.4B in 2026 but net losses widening to $303M, the stock offers asymmetric upside if the company can achieve profitability while maintaining its 25%+ growth trajectory.